4//SEC Filing
Peyer James 4
Accession 0000897069-23-001052
CIK 0001829802other
Filed
Aug 1, 8:00 PM ET
Accepted
Aug 2, 5:06 PM ET
Size
5.1 KB
Accession
0000897069-23-001052
Insider Transaction Report
Form 4
Peyer James
Director10% Owner
Transactions
- Disposition to Issuer
Common Stock
2023-07-31$1.26/sh−1,587,302$2,000,001→ 3,653,120 total(indirect: See footnote)
Footnotes (2)
- [F1]Shares purchased by the Issuer pursuant to a Purchase Agreement, dated July 31, 2023, by and among the Issuer, the Reporting Person and Cambrian BioPharma Inc. This transaction, which was approved by the Board of Directors of the Issuer, is exempt pursuant to Rule 16b-3(e) of the Securities Exchange Act of 1934, as amended.
- [F2]These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.
Documents
Issuer
Sensei Biotherapeutics, Inc.
CIK 0001829802
Entity typeother
Related Parties
1- filerCIK 0001843594
Filing Metadata
- Form type
- 4
- Filed
- Aug 1, 8:00 PM ET
- Accepted
- Aug 2, 5:06 PM ET
- Size
- 5.1 KB